21 May 2021
Shield confirms it remains on track to launch Accrufer® in the US by end of June 2021
Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), provides an update on its preparations to launch Accrufer® in the US, confirming the Group remains on track to launch by end of June 2021. Since the fundraise in mid-March 2021, preparatory work has accelerated dramatically.
For full details, click here.